/
Other
EGFR Mutation
3
Pipeline Programs↗
6
Active Trials↗
9
Companies Involved↗
EGFR Mutation is an early-stage landscape with 3 programs across 9 companies. The most active players are Avistone Biotechnology Co., Ltd., Haisco Pharmaceutical Group Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
36
clinical trials
Unknown status14 · 39%
Completed10 · 28%
Terminated6 · 17%
Recruiting4 · 11%
Not yet recruiting2 · 6%
Clinical Trials
Trial Activity
36 trials
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Completed·—·Phase 2·NCT04184921·216 enrolled
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Completed·—·Phase 2·NCT02769286·38 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)